SPRUCE BIOSCIENCES, INC.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
SPRB$49.34+6.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(53,036) | $(47,919) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 5,348 | 4,622 |
| Depreciation and amortization | 46 | 70 |
| Net accretion of discount on available-for-sale securities | — | (636) |
| Non-cash lease expense | 247 | 230 |
| Loss on disposal of property and equipment | 2 | 2 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 391 | (2,636) |
| Other assets | 494 | 96 |
| Accounts payable | (2,037) | 1,906 |
| Accrued expenses and other current liabilities | (2,271) | 6,255 |
| Deferred revenue | (4,911) | 4,911 |
| Other liabilities | (237) | (176) |
| Net cash used in operating activities | (55,964) | (33,275) |
| Cash flows from investing activities | ||
| Proceeds from maturities of investments | — | 67,665 |
| Purchases of investments | — | (11,881) |
| Purchases of property and equipment | — | (7) |
| Net cash provided by investing activities | — | 55,777 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock and warrants | — | 53,616 |
| Proceeds from issuance of common stock related to employee stock purchase plan | 66 | 169 |
| Proceeds from exercise of pre-funded warrants | — | 8 |
| Proceeds from exercise of common stock options | 180 | 1 |
| Payment of offering costs | — | (2,721) |
| Repayment of term loan | (1,622) | (1,622) |
| Tax withholding payments on restricted stock units | (246) | (311) |
| Net cash provided by (used in) financing activities | (1,622) | 49,140 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | (57,586) | 71,642 |
| Cash, cash equivalents, and restricted cash at beginning of period | 96,374 | 24,732 |
| Cash, cash equivalents, and restricted cash at end of period | $38,788 | $96,374 |
| Reconciliation of cash, cash equivalents, and restricted cash | ||
| Cash and cash equivalents | $38,753 | $96,339 |
| Restricted cash, long-term (included in other assets) | 35 | 35 |
| Total cash, cash equivalents, and restricted cash | $38,788 | $96,374 |
| Supplemental cash flow data: | ||
| Cash paid for interest on term loan | $225 | $369 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Deferred offering costs included in accrued expenses | $— | $51 |
| Right-of-use asset recognized in exchange for lease liability | $— | $11 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.